;
Skip to main content
Home > The Daily Extra > Clinical News

Chronological Index of : Clinical News

 Current Issue
  • CLINICAL NEWS: Omeros suspends Phase II Huntington's trial

    Omeros Corp. (NASDAQ:OMER) was off $1.70 (12%) to $12.12 on Tuesday after suspending a Phase II trial of OMS824 to treat Huntington's disease (HD).Omeros' decision followed an unspecified observation in "several" rats …

    Published on 10/21/2014
  • CLINICAL NEWS: Strong Phase II Crohn's data for Celgene

    Mongersen (GED-0301) from Celgene Corp. (NASDAQ:CELG) produced clinical remission rates as high as 65.1% in a Phase II trial in 166 patients with moderate to severe Crohn's disease, according to an abstract published …

    Published on 10/20/2014
  • CLINICAL NEWS: Regeneron: Eylea bests Avastin, Lucentis in DME

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said top-line data from a comparative effectiveness study using VEGF drugs to treat diabetic macular edema showed its Eylea aflibercept was superior to Avastin bevacizumab …

    Published on 10/17/2014
  • CLINICAL NEWS: ACT boosted on stem cell results

    Advanced Cell Technology Inc. (OTCBB:ACTC) held most of the gain it picked up ahead of Wednesday's online publication of data from a pair of Phase I/II trials showing visual improvements in patients treated with the …

    Published on 10/15/2014
  • CLINICAL NEWS: Novartis, Penn publish Phase I/II CAR T data in ALL

    Novartis AG (NYSE:NVS; SIX:NOVN) and the University of Pennsylvania published in the New England Journal of Medicine results from a Phase I/IIa trial of CTL019 to treat relapsed or refractory acute lymphoblastic …

    Published on 10/15/2014
  • CLINICAL NEWS: Scancell gains on Phase I/II melanoma data

    Scancell Holdings plc (LSE:SCLP; Xetra:SCP) added L3 .75 (12%) to L34 in London on Tuesday after reporting data from an ongoing open-label Phase I/II trial of SCIB1 to treat stage III/IV metastatic melanoma. Among …

    Published on 10/14/2014
  • CLINICAL NEWS: More positive Phase I for Kite's CAR T therapy

    Kite Pharma Inc. (NASDAQ:KITE) said its autologous T cell therapy against CD19 ( KTE-C19) led to a 70% complete response rate in a Phase I trial to treat relapsed or refractory acute lymphoblastic leukemia (ALL). Data …

    Published on 10/13/2014
  • CLINICAL NEWS: NewLink up on human trial of Canada's Ebola vaccine

    The Public Health Agency of Canada said a Phase I trial of VSV-EBOV (BPSC-1001), an experimental Ebola vaccine developed at the country's National Microbiology Lab, has begun at the Walter Reed Army Institute of …

    Published on 10/13/2014
  • CLINICAL NEWS: Isis reports Phase II SMA data

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS) reported data from an ongoing Phase II trial of ISIS-SMNRx to treat infants with spinal muscular atrophy (SMA). The median event-free age of the infants who completed a three-dose…

    Published on 10/10/2014
  • CLINICAL NEWS: Amgen to seek extrapolation for biosimilar Humira

    Amgen Inc. (NASDAQ:AMGN) spokesperson Kelley Davenport said the company will seek to use clinical data for its ABP 501 biosimilar in two indications -- plaque psoriasis and rheumatoid arthritis (RA) -- and extrapolate …

    Published on 10/8/2014
  • CLINICAL NEWS: Arrowhead falls on Phase IIa HBV data

    Arrowhead Research Corp. (NASDAQ:ARWR) dropped $5.48 (44%) to $7.03 on Wednesday after Phase IIa HBV data for ARC-520 fell short of expectations. Arrowhead is studying ARC-520 to treat chronic HBV infection in hepatitis…

    Published on 10/8/2014
  • CLINICAL NEWS: Acacia seeks options after hitting in PONV Phase III

    Acacia Pharma Ltd. (Cambridge, U.K.) said its lead product APD421 reduced the incidence of post-operative nausea and vomiting in two Phase III trials of adult surgical patients at moderate to high risk for PONV. Acacia,…

    Published on 10/7/2014
  • CLINICAL NEWS: Alcobra hammered on intent-to-treat in ADHD

    Alcobra Ltd. (NASDAQ:ADHD) closed down $7.99 (57%) to $6.12 on Monday after Metadoxine ER (MDX), its extended-release formulation of metadoxine, only met the primary endpoint in a Phase III trial to treat adults with …

    Published on 10/6/2014
  • CLINICAL NEWS: Sunesis plummets on Phase III miss in AML

    Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) dropped $5.18 (78%) to $1.46 Monday after its regimen of Qinprezo vosaroxin and cytarabine missed the primary endpoint of improved overall survival (OS) in its Phase III VALOR …

    Published on 10/6/2014
  • CLINICAL NEWS: Lilly halts tabalumab for lupus

    Eli Lilly and Co. (NYSE:LLY) said it will discontinue development of tabalumab to treat systemic lupus erythematosus (SLE) because it failed to show sufficient efficacy in two Phase III trials. The pharma said its …

    Published on 10/2/2014
  • CLINICAL NEWS: Twin Phase IIIs look good for Intarcia

    Intarcia Therapeutics Inc. (Boston, Mass.) said ITCA 650 met all primary and secondary endpoints in two Phase III trials to treat Type II diabetes.ITCA 650 provides patients continuous subcutaneous delivery of exenatide…

    Published on 10/2/2014
  • CLINICAL NEWS: Ardelyx gains on Phase IIb IBS-C data

    Ardelyx Inc. (NASDAQ:ARDX) jumped $4.79 (34%) to $19 on Wednesday after 50 mg tenapanor (RDX5791/AZD1722) met the primary endpoint of increasing complete spontaneous bowel movement (CSBM) responder rate in a Phase IIb …

    Published on 10/1/2014
  • CLINICAL NEWS: Erytech up on Graspa Phase III data

    Erytech Pharma S.A. (Euronext:ERYP) climbed EUR 3.33 (13%) to EUR 29.50 on Wednesday after it said Graspa met the co-primary endpoints in the GRASPIVOTALL Phase III trial to treat children and adults with relapsed or …

    Published on 10/1/2014
  • CLINICAL NEWS: Portola lifted on Phase III data

    Portola Pharmaceuticals Inc. (NASDAQ:PTLA) gained $4.04 (16%) to $29.32 on Wednesday after its andexanet alfa met the primary and secondary endpoints in a Phase III study to reverse the anticoagulant activity of Eliquis…

    Published on 10/1/2014
  • CLINICAL NEWS: Catalyst's Firdapse meets in LEMS Phase III

    Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX) said its oral potassium channel blocker Firdapse amifampridine met the co-primary endpoints in a Phase III trial to treat Lambert-Eaton myasthenic syndrome (LEMS). In …

    Published on 9/29/2014
  • CLINICAL NEWS: Genentech unveils OS benefit for Perjeta combo

    The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) presented Phase III data showing that Perjeta pertuzumab in combination with Herceptin trastuzumab and docetaxel chemotherapy increased the overall survival (OS) …

    Published on 9/29/2014
  • CLINICAL NEWS: PARP ovarian data boosts Clovis

    Clovis Oncology Inc. (NASDAQ:CLVS) gained $5.59 (13%) to $48.08 on Monday after presenting results from two trials evaluating rucaparib (CO-338) for platinum-sensitive ovarian cancer at the European Society of Medical …

    Published on 9/29/2014
  • CLINICAL NEWS: Seattle Genetics: More Adcetris data at ASH

    Seattle Genetics Inc. (NASDAQ:SGEN) was off $2.98 to $38.30 on Monday after reporting Adcetris brentuximab vedotin met the primary endpoint of improving progression-free survival (PFS) vs. placebo (HR=0.57, p=0.001) in …

    Published on 9/29/2014
  • CLINICAL NEWS: Tonix plummets on Phase IIb miss

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) fell $7.01 (50%) to $6.95 on Monday after its TNX-102 SL missed the primary endpoint in a Phase IIb trial to treat fibromyalgia. In the 205-patient BESTFIT study, 2.8 mg…

    Published on 9/29/2014
  • CLINICAL NEWS: Repros gains on second Androxal Phase III

    Repros Therapeutics Inc. (NASDAQ:RPRX) gained $1.52 (17%) to $10.48 on Friday after its Androxal enclomiphene met both primary endpoints in the Phase III ZA-304 trial to treat secondary hypogonadism, which measured the …

    Published on 9/26/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993